Richard, due to the respect that Rainier shows in you and your obvious credentials, I would sincerely appreciate your further critique.
I'm a clinical analyst, but am obviously nowhere close to your league.
Today's release about the vaccines gave some more specifics of the method of action than than others before. Perhaps this addresses your concerns, perhaps not. Could you possibly comment?
<<Dr. Bucalo continued, ''We believe that previously reported Phase I/II clinical testing of Titan's therapeutic cancer vaccines has demonstrated very compelling data regarding strong immune responses elicited with our vaccines. In order for cancer vaccines to have a reasonable basis for a therapeutic benefit, these types of products should generate tumor antigen specific immune responses in the large majority of patients. In addition to being tumor antigen specific, the antibody responses should be sustained and polyclonal, encompassing both IgG and IgM subtypes. This is important, because while IgM allows the potential for complement mediated tumor destruction, IgG enables cell mediated tumor killing, and it is important to enable both potential mechanisms of tumor killing. In addition, there should be evidence of T-cell activation which is again specific to the tumor antigen. In studies performed to date, Titan's vaccines are distinguished by fulfilling all these criteria.''>>
Also, I thought the design of the study was fairly good, and your comments on this issue would be welcome.
Miljenko, I would also greatly appreciate your insight, and understand your efforts to balance investment and family needs.
Scott |
